T-Cypher Bio Expands Oxford Lab Space for TCR Pipeline

Oxford-based biotech T-Cypher Bio has relocated to a 12,000 sq ft purpose-built facility at Abingdon Science Park, supporting its pipeline of TCR-based T cell engager therapies for solid tumours and autoimmune disease. Announced on 11 November 2026, the move extends the company’s laboratory footprint at a critical point in its progress toward clinical development, reinforcing the growing Oxford life sciences cluster and adding further weight to the UK’s emerging immuno-oncology biotech infrastructure.

The new facility at Barton House is a newly built, purpose-built site developed by Kadans Science Partner within the 500,000 sq ft Abingdon Science Park campus. It provides Containment Level 2 wet laboratories and open-plan offices, with expanded tissue culture space to support in vitro work for IND-enabling studies. Sarah Leonard, CEO of T-Cypher Bio, framed the move around expanded tissue culture capacity and the ability to shape the design of the new site around the company’s specialist laboratory needs. Katie Nelson, Head of Leasing UK&I at Kadans Science Partner, positioned the fit-out around accommodating specialist laboratory infrastructure. Other tenants at Abingdon Science Park include Penlon, Alethio Therapeutics, Sense Bio and Capgemini, with Kadans’ broader European life sciences network opening collaboration and partnership opportunities.

T-Cypher Bio was founded as a deep tech company and operates a discovery platform and machine-learning engine, T-C Alpha (T-Ca), which profiles the human disease target space and associated T cell reactivity, combining computational and wet-lab systems to identify high copy number targets. The company’s TCR-based T cell engager strategy sits within the growing immune engager therapeutic category, where recent big pharma activity has included Roche’s $813m Zymeworks ZW209 DLL3 TCE deal and multiple ADC and TCE China-origin licensing deals, reinforcing the commercial attractiveness of the modality. The Oxford expansion complements the broader UK life sciences investment story, including recent big pharma commitments across the Oxford, Cambridge and Manchester clusters. Lease terms, costs and investment amounts were not disclosed.

The commercial signal is a continued build-out of UK immuno-oncology biotech infrastructure, with purpose-built Oxford laboratory capacity anchoring T-Cypher Bio’s clinical progression and the broader Abingdon Science Park cluster. IND-enabling study progression remains the key near-term milestone. Expect sustained UK life sciences infrastructure investment and continued focus on TCR-based T cell engager platforms through 2027 and 2028.

For the latest updates and in-depth insights into the world of Pharmaceuticals, including breakthrough treatments, industry trends, and regulatory news, contact Katie Ginger today!